Concepedia

Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes

Heike Zimdahl, Axel Haupt, Michael Brendel, Louis Bour, Fausto Machicao, Afshin Salsali, Uli C. Broedl, Hans‐Juergen Woerle, Hans‐Ulrich Häring, Harald Staiger

Pharmacogenetics and Genomics · 2017 · 47 citations · 19 references

DOIFull text

Open access

Abstract

Common genetic variants in the SLC5A2 gene neither affects diabetes-related metabolic traits nor have a clinically relevant impact on response to treatment with the SGLT2 inhibitor empagliflozin.

References

19

DNA sequencing with chain-terminating inhibitors

Frederick Sanger, S. Nicklen, Alan Coulson · Proceedings of the National Academy of Sciences · 1977 · 69.1K citations · Full text

, , +20

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

David R. Matthews, J P Hosker, A. Rudenski et al. · Diabetologia · 1985 · 31K citations · Full text

, , +13

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Andrew S. Levey, Juan Bosch, Julia B. Lewis et al. · Annals of Internal Medicine · 1999 · 15K citations

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Masafumi Matsuda, Ralph A. DeFronzo · Diabetes Care · 1999 · 5.5K citations

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Roden, Jianping Weng, Jens Eilbracht et al. · The Lancet Diabetes & Endocrinology · 2013 · 438 citations

, , +8